+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030

  • ID: 5116514
  • Report
  • April 2020
  • Region: Global
  • 536 Pages
  • Roots Analysis
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3D Medicines
  • Beta-O2 Technologies
  • Elektrofi
  • Intrexon
  • Numab
  • Shreya Life Sciences
  • MORE

Overview

Biologics represent one of the fastest growing classes of therapeutic molecules in modern healthcare. As per an article published in January 2020, the annual global biologics market is expected to be approximately USD 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to conventional pharmaceuticals. Considering the necessity to bypass gastric metabolism, biologics are mostly designed for administration via parenteral routes. In fact, majority of such therapies are formulated for intravenous delivery and are usually administered in a clinical setting (hospitals / infusion centers). However, this scenario is cost intensive and is known to be associated with medication adherence related concerns. In this context, the subcutaneous route of drug delivery offers a number of benefits, including self-medication and life cycle management options. Although the pharmacokinetic profiles of intravenous and subcutaneous formulations are different, studies have demonstrated that the latter formulations are preferred by end users (patients and healthcare providers), offering substantial cost saving opportunities.

Presently, the subcutaneous delivery option is being investigated for a number of clinical candidates across different phases of development. Moreover, several approved therapeutic products, which are currently available in intravenous dosage forms, are also being reformulated and evaluated for subcutaneous administration. However, there are certain concerns associated with the subcutaneous route. For instance, most protein-based therapeutics, such as monoclonal antibodies, need to be administered in large quantities and have been shown to result in highly viscous formulations when reformulated for subcutaneous delivery.

In order to address this particular challenge, many companies have developed / are developing a number of novel technology platforms to facilitate the delivery of viscous drug formulations. Similar innovations are gradually facilitating a shift to subcutaneous delivery, primarily driven by the demand for self-administrable therapeutics. In fact, there are several self-medication solutions, equipped with a variety of user-friendly features, available in the market; examples include prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors. Over the past few years, the aforementioned drug-device combination products have witnessed high adoption, enabled substantial reductions in healthcare expenses (incurred by patients), and improved therapy adherence. In this regard, the rising incidence of chronic clinical conditions (which are characterized by the need for frequent medication) and the ongoing efforts of therapy / device developers engaged in this field, are anticipated to drive the growth of the subcutaneous biologics market in the coming years.

Scope of the Report

The ‘Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030’ report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs.

Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of commercially available and clinical-stage biologics that are designed for delivery via the subcutaneous route, along with information on approval year, phase of development, type of pharmacological molecule, target  therapeutic area, dosing frequency, available dosage forms and key players.
  • A case study on leading subcutaneous biologics (in terms of revenues generated), featuring details on mechanism of action, development history, annual sales, technology platform (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).
  • An assessment of the various subcutaneous formulation technologies along with information on developers, type of pharmacological molecule, route of administration, mechanisms of action and primary advantage(s).
  • An insightful three-dimensional comparison of the subcutaneous formulation technology developers, based on pipeline strength (number of drugs developed using a particular technology), supplier power (number of years of experience and company size) of the developer and primary advantages offered by their respective technologies. Also, the study includes a detailed benchmark analysis of the technology developers based in North America and Europe, highlighting the primary advantage(s) offered by their proprietary technologies, applicability to other types of pharmacological molecules, and other possible routes of drug administration.
  • Elaborate profiles of key technology developers, featuring a brief overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook.
  • An analysis of collaborations  and partnership agreements inked by the subcutaneous formulation technology developers since 2011; it includes details of deals that were / are focused on subcutaneous formulation technologies, which were analyzed on the basis of year of agreement, type of agreement, and upfront and milestone payments.
  • An in-depth review of the most advanced and popular subcutaneous drug delivery systems, including large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants, providing information on their developer(s) and device specific features. Details of specific parameters captured for different device categories are mentioned as follows:
  • Large volume wearable injectors: Stage of development (commercialized and under development), type of device (infusion pump and patch pump), type of dose administered (continuous and bolus), volume / storage capacity (in mL), mode of injection (needle, needle / cannula and needle / catheter) and mechanism of action (driving force).
  • Autoinjectors: Usability (disposable and reusable), type of primary container (syringe, cartridge and others), volume / storage capacity (in mL), type of dose (fixed dose and variable dose) and actuation mechanism (automatic, semi-automatic and manual).
  • Pen injectors: Usability (disposable and reusable), volume / storage capacity (in mL), and type of  dose (fixed dose and variable dose).
  • Needle-free injection systems: Stage of development (commercialized and under development), volume / storage capacity (in mL), usability (disposable and reusable), and actuation mechanism (spring-based, gas-powered and others).
  • Drug reconstitution systems: Usability (disposable and reusable), device type (dual chambered systems and other novel systems) and type of drug container (cartridge, vials and others).
  • Prefilled syringes: Barrel fabrication material (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and volume / storage capacity (in mL).
  • Implants: Stage of development (commercialized and under development), target therapeutic area, implant material (silicone, titanium, polymers and others) and treatment duration.
  • A comprehensive product competitiveness analysis of subcutaneous large volume wearable injectors, subcutaneous autoinjectors, subcutaneous needle-free injectors and pre-filled syringes, taking into consideration the supplier power and product specific information.
  • A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry’s evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous products market.

One of the key objectives of this study was to understand the primary growth drivers and estimate the existing market size and the future growth potential of the subcutaneous biologics, technologies and drug delivery systems market. Based on historical trends and sales related information for subcutaneous biologic drugs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] phase of development (approved, preregistration & phase III and phase II & phase II/III)), [B] type of pharmacological molecule (proteins, peptides (recombinant), monoclonal antibodies, other antibody based products, cell / gene therapies and vaccines), [C] target therapeutic areas (autoimmune disorders, metabolic disorders, blood disorders, bone disorders, oncological disorders, genetic disorders, neurological disorders, respiratory disorders and other disorders) and [D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition to the market forecast for subcutaneous biologic drugs, we have also provided a 10-year forecast for subcutaneous delivery systems, covering the market for large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injectors and drug reconstitution systems. Further, we have also forecasted the revenues that subcutaneous formulation technology developers are likely to generate through licensing agreements; for this, we have provided a view on the likely upfront payments and milestone payments that will be generated from the deals related to the development of subcutaneous formulation of biologics. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain.

The report features detailed transcripts of interviews held with the following individuals:

  • Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences)
  • Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies)
  • Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals), Hong Qi ( Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Sr. Scientist Formulation, Xeris Pharmaceuticals)
  • David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices)
  • Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio)
  • Poonam R Velagaleti (Co-Founder, i-novion)
  • Michael Hooven (Chief Executive Officer, Enable Injections)
  • Frederic Ors (Chief Executive Officer, Immunovaccine Technologies)
  • Patrick Anquetil (Chief Executive Officer, Portal Instruments)
  • Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
  • Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services)
  • David Heuzé (Communication Leader, MedinCell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3D Medicines
  • Beta-O2 Technologies
  • Elektrofi
  • Intrexon
  • Numab
  • Shreya Life Sciences
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Therapeutic Molecules
3.3. Biologically Derived Therapeutics
3.3.1. Types of Products
3.3.2. Routes of Administration and Formulations
3.3.3. Subcutaneous Formulations
3.3.3.1. Approaches in Subcutaneous Delivery of Biologics
3.3.3.1.1. Reformulation
3.3.3.1.2. Differing Potencies
3.3.3.1.3. Novel Technologies
3.3.3.2. Method of Subcutaneous Administration
3.3.3.3. Advantages of Subcutaneous Administration
3.3.3.4. Limitations of Subcutaneous Administration
3.4. Regulatory Considerations
3.4.1. Medical Devices
3.4.2. Drug Device Combination Products
3.5. Future Perspectives
 
4. SUBCUTANEOUS BIOLOGICS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Subcutaneous Administration of Biologics
4.3. Subcutaneous Biologics: List of Approved Drugs
4.3.1. Analysis by Approval Year
4.3.2. Analysis by Type of Pharmacological Molecule
4.3.3. Analysis by Target Therapeutic Area
4.3.4. Analysis by Type of Formulation
4.3.5. Analysis by Dosing Frequency
4.3.6. Analysis by Dosage Form
4.3.7. Key Players: Analysis by Number of Drugs Approved
4.4. Subcutaneous Biologics: List of Clinical-Stage Drug Candidates
4.4.1. Analysis by Phase of Development
4.4.2. Analysis by Type of Pharmacological Molecule
4.4.3. Analysis by Target Therapeutic Area
4.4.4. Analysis by Dosing Frequency
4.4.5. Key Players: Analysis by Number of Drug Candidates in Trials

5. CASE STUDY: LEADING SUBCUTANEOUS BIOLOGICS
5.1. Chapter Overview
5.2. Subcutaneous Biologics: Leading Drugs by Annual Sales
5.3. Case Studies
5.3.1. HUMIRA® (AbbVie, Eisai)
5.3.1.1. Drug Overview
5. 3.1.2. Development History
5. 3.1.3. Target Indications and Dosage Forms
5. 3.1.4. Historical Sales
5.3.2. Enbrel® (Amgen, Pfizer, Takeda Pharmaceutical)
5.3.2.1. Overview
5. 3.2.2. Development History
5. 3.2.3. Target Indications and Dosage Forms
5. 3.2.4. Historical Sales
5.3.3. RITUXAN® / MabThera® (Biogen, Roche, Chugai Pharmaceutical)
5.3.3.1. Overview
5. 3.3.2. Development History
5. 3.3.3. Target Indications and Dosage Forms
5. 3.3.4. Historical Sales
5. 3.3.5. ENHANZE™ Technology (Halozyme Therapeutics)
5. 3.3.6. Advantages of Subcutaneous RITUXAN® / MabThera® Over Intravenous RITUXAN® / MabThera®
5.3.4. Herceptin® (Roche, Chugai Pharmaceutical)
5.3.4.1. Overview
5. 3.4.2. Development History
5. 3.4.3. Target Indications and Dosage Forms
5. 3.4.4. Historical Sales
5. 3.4.5. ENHANZE™ Technology (Halozyme Therapeutics)
5. 3.4.6. Advantages of Subcutaneous Herceptin® Over Intravenous Herceptin®
5. 3.4.7. Herceptin® - Large Volume Wearable Injector Combination Product
5.3.5. Neulasta® (Amgen, Kyowa Hakko Kirin)
5.3.5.1. Overview
5.3.5.2. Development History
5.3.5.3. Target Indications and Dosage Forms
5.3.5.4. Historical Sales

6. SUBCUTANEOUS FORMULATION TECHNOLOGIES: CURRENT MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Subcutaneous Formulation Technologies: List of Technology Developers
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Geographical Location
6.3. Subcutaneous Formulation Technologies: List of Technologies
6.3.1. Analysis by Type of Pharmacological Molecule
6.3.2. Analysis by Route of Administration
6.3.3. Analysis by Advantage(s) Offered

7. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Subcutaneous Formulation Technology Developers: Competitive Landscape
7.2.1. Methodology
7.2.2. Three-Dimensional Bubble Analysis based on Supplier Power, Pipeline Strength and Primary Advantage(s)
7.3. Subcutaneous Formulation Technology Developers: Benchmark Analysis
7.3.1. Methodology
7.3.2. North America
7.3.3. Europe

8. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY PROFILES
8.1. Chapter Overview
8.2. Adocia
8.2.1. Company Overview
8.2.2. Technology Overview
8.2.2.1. BioChaperone® Technology
8.2.3. Product Portfolio
8.2.4. Financial Performance
8.2.5. Recent Developments and Future Outlook
8.3. Ajinomoto Althea
8.3.1. Company Overview
8.3.2. Technology Overview
8.3.2.1. Crystalomics® Formulation Technology
8.3.3. Product Portfolio
8.3.4. Financial Performance
8.3.5. Recent Developments and Future Outlook
8.4. Arecor
8.4.1. Company Overview
8.4.2. Technology Overview
8.4.2.1. Arestat™ Technology
8.4.3. Product Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Alteogen
8.5.1. Company Overview
8.5.2. Technology Overview
8.5.2.1. Hybrozyme Technology
8.5.3. Product Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. Ascendis Pharma
8.6.1. Company Overview
8.6.2. Technology Overview
8.6.2.1. TransCon Technology
8.6.3. Product Portfolio
8.6.4. Financial Performance
8.6.5. Recent Developments and Future Outlook
8.7. Avadel Pharmaceuticals
8.7.1. Company Overview
8.7.2. Technology Overview
8.7.2.1. Medusa™ Technology
8.7.3. Product Portfolio
8.7.4. Financial Performance
8.7.5. Recent Developments and Future Outlook
8.8. Camurus
8.8.1. Company Overview
8.8.2. Technology Overview
8.8.2.1. FluidCrystal® Injection Depot Technology
8.8.3. Product Portfolio
8.8.4. Financial Performance
8.8.5. Recent Developments and Future Outlook
8.9. Creative BioMart
8.9.1. Company Overview
8.9.2. Technology Overview
8.9.2.1. High Concentration Formulation Technology
8.9.3. Product Portfolio
8.9.4. Recent Developments and Future Outlook
8.10. Creative Biolabs
8.10.1. Company Overview
8.10.2. Technology Overview
8.10.2.1. Long-Acting Injectable Technology
8.10.3. Product Portfolio
8.10.4. Recent Developments and Future Outlook
8.11. DURECT
8.11.1. Company Overview
8.11.2. Technology Overview
8.11.2.1. SABER® Platform
8.11.2.2. CLOUD™ PLATFORM
8.11.3. Product Portfolio
8.11.4. Financial Performance
8.11.5. Recent Developments and Future Outlook
8.12. Eagle Pharmaceuticals
8.12.1. Company Overview
8.12.2. Technology Overview
8.12.2.1. Unnamed Technology
8.12.3. Product Portfolio
8.12.4. Financial Performance
8.12.5. Recent Developments and Future Outlook
8.13. Halozyme Therapeutics
8.13.1. Company Overview
8.13.2. Technology Overview
8.13.2.1. ENHANZE® Technology
8.13.3. Product Portfolio
8.13.4. Financial Performance
8.13.5. Recent Developments and Future Outlook
8.14. MedinCell
8.14.1. Company Overview
8.14.2. Technology Overview
8.14.2.1. BEPO® Technology
8.14.3. Product Portfolio
8.14.4. Recent Developments and Future Outlook
8.15. Xeris Pharmaceuticals
8.15.1. Company Overview
8.15.2. Technology Overview
8.15.2.1. XeriJect™ Technology
8.15.2.2. XeriSol™ Technology
8.15.3. Product Portfolio
8.15.4. Recent Developments and Future Outlook
8.16. Serina Therapeutics
8.16.1. Company Overview
8.16.2. Technology Overview
8.16.2.1. POZ™ Drug Delivery Technology
8.16.3. Product Portfolio
8.16.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Subcutaneous Formulation Technologies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Regional Analysis
9.3.5. Intercontinental and Intracontinental Agreements

10. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: CURRENT MARKET LANDSCAPE
10.1. Chapter Overview
10.2. Different Types of Subcutaneous Drug Delivery Systems
10.3. Subcutaneous Drug Delivery Systems: Overall Market Landscape
10.3.1. Large Volume Wearable Injectors
10.3.1.1. Overview
10.3.1.2. Current Market Landscape of Devices for Non-insulin Biologics
10.3.1.2.1. Analysis by Stage of Development
10.3.1.2.2. Analysis by Type of Device
10.3.1.2.3. Analysis by Type of Dose Administered
10.3.1.2.4. Analysis by Volume / Storage Capacity
10.3.1.2.5. Analysis by Usability
10.3.1.2.6. Analysis by Mode of Injection
10.3.1.2.7. Analysis by Mechanism of Action
10.3.1.2.8. Most Active Players: Analysis by Number of Devices
10.3.1.2.9. Product Competitiveness Analysis
10.3.1.3. Current Market Landscape of Devices for Insulin10.3.1.3.1.Analysis by Stage of Development
10.3.1.3.2. Analysis by Type of Device
10.3.1.3.3. Analysis by Volume / Storage Capacity
10.3.1.3.4. Analysis by Usability
10.3.1.3.5. Analysis by Availability of Integrated CGM / BGM System
10.3.1.3.6. Most Active Players: Analysis by Number of Devices
10.3.1.3.7 Product Competitiveness Analysis
10.3.2. Autoinjectors
10.3.2.1. Overview
10.3.2.2. Current Market Landscape
10.3.2.2.1. Analysis by Usability
10.3.2.2.2. Analysis by Type of Primary Container
10.3.2.2.3. Analysis by Volume / Storage Capacity
10.3.2.2.4. Analysis by Type of Dose
10.3.2.2.5. Analysis by Actuation Mechanism
10.3.2.2.6. Most Active Players: Analysis by Number of Devices
10.3.2.2.7. Product Competitiveness Analysis
10.3.2.3. Drug Device Combination Products
10.3.3. Pen Injectors
10.3.3.1. Overview
10.3.3.2. Current Market Landscape
10.3.3.2.1. Analysis by Usability
10.3.3.2.2. Analysis by Volume / Storage Capacity
10.3.3.2.3. Analysis by Type of Dose
10.3.3.2.4. Most Active Players: Analysis by Number of Devices
10.3.3.3. Drug Device Combination Products
10.3.4. Needle-Free Injection Systems
10.3.4.1. Overview
10.3.4.2. Current Market Landscape
10.3.4.2.1. Analysis by Stage of Development
10.3.4.2.2. Analysis by Volume / Storage Capacity
10.3.4.2.3. Analysis by Usability
10.3.4.2.4. Analysis by Actuation Mechanism
10.3.4.2.5. Most Active Players: Analysis by Number of Devices
10.3.4.2.6. Product Competitiveness Analysis
10.3.5. Drug Reconstitution Delivery Systems
10.3.5.1. Overview
10.3.5.2. Current Market Landscape
10.3.5.2.1. Analysis by Usability
10.3.5.2.2. Analysis by Type of Device
10.3.5.2.3. Analysis by Type of Drug Container
10.3.5.2.4. Most Active Players: Analysis by Number of Devices
10.3.6. Prefilled Syringes
10.3.6.1. Overview
10.3.6.2. Current Market Landscape
10.3.6.2.1. Analysis by Barrel Fabrication Material
10.3.6.2.2. Analysis by Number of Barrel Chambers
10.3.6.2.3. Analysis by Type of Needle System
10.3.6.2.4. Analysis by Volume / Storage Capacity
10.3.6.3.5. Most Active Players: Analysis by Number of Devices
10.3.6.3. Product Competitiveness Analysis
10.3.6.4. Drug Device Combination Products
10.3.7. Implants
10.3.7.1. Overview
10.3.7.2. Current Market Landscape
10.3.7.2.1. Analysis by Stage of Development
10.3.7.2.2. Analysis by Target Therapeutic Area
10.3.7.2.3. Analysis by Implant Material
10.3.7.2.4. Analysis by Treatment Duration
10.3.7.2.5. Most Active Players: Analysis by Number of Devices

11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Comparison of SWOT Factors
11.2.1. Strengths
11.2.2. Weaknesses
11.2.3. Opportunities
11.2.4. Threats

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Subcutaneous Biologics Market
12.2.1. Forecast Methodology and Key Assumptions
12.2.2. Overall Subcutaneous Biologics Market, 2020-2030
12.2.2.1. Subcutaneous Biologics Market, 2020-2030: Distribution by Phase of Development
12.2.2.2. Subcutaneous Biologics Market, 2020-2030: Distribution by Type of Pharmacological Molecule
12.2.2.3. Subcutaneous Biologics Market, 2020-2030: Distribution by Target Therapeutic Area
12.2.2.4. Subcutaneous Biologics Market, 2020-2030: Distribution by Key Geographical Regions
12.3. Subcutaneous Drug Delivery Systems Market
12.3.1. Device Type 1: Large Volume Wearable Injectors
12.3.1.1. Forecast Methodology and Key Assumptions
12.3.1.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030
12.3.1.2.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030
12.3.1.2.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030
12.3.1.2.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Target Therapeutic Area, 2020-2030
12.3.1.2.4. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Key Geographical Regions, 2020-2030
12.3.1.3. Global Large Volume Wearable Injectors Market for Insulin, 2020-2030
12.3.1.3.1. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030
12.3.1.3.2. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030
12.3.1.3.3. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Key Geographical Regions, 2020-2030
12.3.2. Device Type 2: Autoinjectors
12.3.2.1. Forecast Methodology and Key Assumptions
12.3.2.2. Global Autoinjectors Market, 2020-2030
12.3.2.2.1. Global Autoinjectors Market: Distribution by Usability, 2020-2030
12.3.2.2.2. Global Autoinjectors Market: Distribution by Type of Pharmacological Molecule, 2020-2030
12.3.2.2.3. Global Autoinjectors Market: Distribution by Key Geographical Regions, 2020-2030
12.3.3. Device Type 3: Prefilled Syringes
12.3.3.1. Forecast Methodology and Key Assumptions
12.3.3.2. Global Prefilled Syringes Market, 2020-2030
12.3.3.2.1. Global Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020-2030
12.3.3.2.2. Global Prefilled Syringes Market: Distribution by Type of Chamber System, 2020-2030
12.3.3.2.3. Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020-2030
12.3.3.2.4. Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030
12.3.3.2.5. Global Prefilled Syringes Market: Distribution by Key Geographical Regions, 2020-2030
12.3.4. Device Type 4: Needle-Free Injection Systems
12.3.4.1. Forecast Methodology and Key Assumptions
12.3.4.2. Global Needle-Free Injection Systems Market, 2020-2030
12.3.4.2.1. Global Needle-Free Injection Systems Market: Distribution by Usability, 2020-2030
12.3.4.2.2. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2020-2030
12.3.4.2.3. Global Needle-Free Injection Systems Market: Distribution by Target Therapeutic Area, 2020-2030
12.3.4.2.4. Global Needle-Free Injection Systems Market: Distribution by Key Geographical Regions, 2020-2030
12.3.5. Device Type 5: Novel Drug Reconstitution Systems
12.3.5.1. Forecast Methodology and Key Assumptions
12.3.5.2. Global Novel Drug Reconstitution Systems Market, 2020-2030
12.4. Subcutaneous Formulation Technologies Market
12.4.1. Subcutaneous Formulation Technologies Market: Distribution by Upfront and Milestone Payments, 2020-2030

13. CONCLUDING REMARKS

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Lindy Biosciences
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Deborah Bitterfield, Chief Executive Officer and Founder
14.3. Oval Medical Technologies
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Matthew Young, Chief Technology Officer and Founder
14.4. Xeris Pharmaceuticals
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Steve Prestrelski, Chief Scientific Officer and Founder; Hong Qi, Vice President, Product Development; and Scott Coleman, Sr. Scientist Formulation)
14.5. DALI Medical Devices
14.5.1. Company Snapshot
14.5.2. Interview Transcript: David Daily, Chief Executive Officer and Co-Founder
14.6. Excelse Bio
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Michael Reilly, Chief Executive Officer and Co-Founder
14.7. i-novion
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Poonam R Velagaleti, Co-Founder
14.8. Enable Injections
14.8.1. Company Snapshot
14.8.2. Interview Transcript: Michael Hooven, Chief Executive Officer
14.9. Immunovaccine Technologies
14.9.1. Company Snapshot
14.9.2. Interview Transcript: Frederic Ors, Chief Executive Officer
14.10. Portal Instruments
14.10.1. Company Snapshot
14.10.2. Interview Transcript: Patrick Anquetil, Chief Executive Officer
14.11. Elcam Medical
14.11.1. Company Snapshot
14.11.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist
14.12. West Pharmaceutical Services
14.12.1. Company Snapshot
14.12.2. Interview Transcript: Tiffany H Burke, Director, Global Communications and Graham Reynolds, Vice President and General Manager, Global Biologics
14.13. MedinCell
14.13.1. Company Snapshot
14.13.2. Interview Transcript: David Heuzé, Communication Leader

15. APPENDIX 1:  TABULATED DATA

Note: Product cover images may vary from those shown
3 of 4
  • 3D Medicines
  • AB2 Bio
  • Abbott Laboratories
  • AbbVie
  • Ablynx
  • AC Immune
  • Acceleron Pharma
  • Accord Healthcare
  • Acer Therapeutics
  • ACG Management
  • Activa Brand Products
  • Adisave
  • Adocia
  • Affibody
  • Affinivax
  • Aguettant
  • Aijex Pharma International
  • Ajinomoto Bio-Pharma Services
  • Akcea Therapeutics
  • Akeso Tiancheng
  • AKRA DERMOJET
  • AktiVax
  • Alder BioPharmaceuticals
  • Alexion
  • Alkermes
  • Allergan
  • Alnylam Pharmaceuticals
  • Alopexx Oncology
  • Alphamab
  • Alteogen
  • Altor BioScience
  • ALTuCELL
  • Altus Pharmaceuticals
  • Alvogen
  • ALZA
  • AMAG Pharmaceuticals
  • Amedra Pharmaceuticals
  • Amgen
  • Amgen Astellas BioPharma
  • AnaptysBio
  • Androsystems
  • Antares Pharma
  • Anterogen
  • Anthera Pharmaceuticals
  • Aphios
  • Apobiologix
  • Apotex
  • Araclon Biotech
  • Arecor
  • argenx
  • ARMO BioSciences
  • Arsia Therapeutics
  • ARTE
  • Asahi Kasei
  • Ascendis Pharma
  • ASIT Biotech
  • ASLAN Pharmaceuticals
  • Aspen Pharmacare
  • Astellas Pharma
  • AstraZeneca
  • Athyrium Capital Management
  • Atridia
  • Avadel Pharmaceuticals
  • Avant Medical Corporation
  • Avid Bioservices
  • Avillion
  • Axxia Pharmaceuticals
  • BASF
  • Bavarian Nordic
  • Baxalta
  • Bay City Capital
  • Bayer
  • Becton Dickinson
  • Beijing Dongfang Biotech
  • Beijing Northland Biotech
  • Bespak
  • Beta-Cell
  • Beta-O2 Technologies
  • Bill & Melinda Gates Foundation
  • Bioam Gestion
  • BioAtla
  • BIOCAD
  • Biocorp
  • Biogen
  • Bioject Medical Technologies
  • BioMarin Pharmaceutical
  • Biomay
  • BioValve
  • Bird Rock Bio
  • Boehringer Ingelheim
  • Boston Pharmaceuticals
  • Braeburn Pharmaceuticals
  • Bristol-Myers Squibb
  • Britannia Pharmaceuticals
  • Broadfin Capital
  • Cadila Pharmaceuticals
  • Calibr
  • Cam Med
  • Cambridge Antibody Technology
  • Cambridge Consultants
  • Camurus
  • Carbion
  • Catalyst Biosciences
  • CDC Enterprises
  • Celgene
  • Celldex Therapeutics
  • Cellnovo
  • Central Texas Angel Network
  • CeQur
  • Chondrial Therapeutics
  • Chugai Pharmaceutical
  • CinnaGen
  • Cleveland BioLabs
  • CM-CIC Innovation
  • College Diabetes Network
  • Companion Medical
  • Complex Biosystems
  • Copernicus
  • Corbion
  • Corvidia Therapeutics
  • Creative Biolabs
  • Creative BioMart
  • Crescendo Pharmaceuticals
  • Crossject
  • CSL Behring
  • CSPC Pharmaceutical
  • C-Tri
  • Cumberland Pharmaceuticals
  • CuraVac
  • CytoDyn
  • Cytori Therapeutics
  • Daiichi Sankyo
  • Daikyo Seiko
  • DALI Medical Devices
  • D'Antonio Consultants International
  • Debiotech
  • Deerfield Management
  • Delpor
  • DelSiTech
  • Dermira
  • Desentum
  • DiaMedica Therapeutics
  • Diamesco
  • Diasome Pharmaceuticals
  • Digital Medics
  • Digna Biotech
  • Dongbao
  • Dr. Reddy's Laboratories
  • DSM Venturing
  • Duoject Medical Systems
  • DURECT
  • Dyax (acquired by Shire)
  • Eagle Pharmaceuticals
  • Eddingpharm
  • Eiger BioPharmaceuticals
  • Eisai
  • Elcam Medical
  • Elektrofi
  • Eli Lilly
  • EMD Serono
  • Emergent BioSolutions
  • Emperra
  • Enable Injections
  • Endo Pharmaceuticals
  • Enesi Pharma
  • EOC Pharma
  • Epilepsy Foundation
  • Etubics
  • European Pharma Group
  • Ever Supreme Bio Technology
  • Excelse Bio
  • EyeTech
  • Felton International
  • Ferring Pharmaceuticals
  • Finox Biotech
  • Flamel Technologies
  • Flowonix Medical
  • FluGen
  • Fresenius Kabi
  • FUJIFILM Diosynth Biotechnologies
  • Future Injection Technologies
  • Fuze
  • GALVmed
  • GC Pharma
  • Genentech
  • Generon
  • Genexine
  • Genmab
  • Genor Biopharma
  • GEROPHARM
  • Gerresheimer
  • Gilde Healthcare
  • Gilead Sciences
  • GlaxoSmithKline
  • Globe Medical Tech
  • GlobeImmune
  • Grifols
  • HAL Allergy
  • Halozyme Therapeutics
  • Hanall Biopharma
  • Hanmi Pharmaceutical
  • Harbour BioMed
  • Haselmeier
  • Health Decisions
  • Hercules Capital
  • Heron Therapeutics
  • Hikma Pharmaceuticals
  • Hospira
  • Human Genome Sciences
  • IDINVEST Partners
  • ILTOO Pharma
  • Il-Yang Pharmaceutical
  • Immunex
  • Immunomedics
  • ImmunoVaccine Technologies
  • ImmusanT
  • Immutep
  • Impax Laboratories
  • Incepta Pharmaceuticals
  • Indivior
  • Injecto
  • INJEX Pharma
  • Inmunotek
  • InnoCore Pharmaceuticals
  • Innovare R&D
  • Innovate UK
  • Innovent Biologics
  • Inolife Sciences
  • Inovio Pharmaceuticals
  • i-novion
  • Insense
  • Insulet
  • Insuline Medical
  • Intarcia Therapeutics
  • Integrity Bio
  • Intrexon
  • Ipsen
  • ISU Abxis
  • Izana Bioscience
  • Janssen
  • Janus Capital
  • JCR Pharmaceuticals
  • JDRF
  • Jiangsu Delfu Medical Device
  • Jiangsu Hengrui Medicine
  • Jiangsu Wan Hai Medical Instruments
  • JO Pharma
  • Johnson & Johnson
  • Juvenile Diabetes Research Foundation
  • Kaléo
  • Kangstem Biotech
  • Kastle Therapeutics
  • KBI Biopharma
  • Kedrion Biopharma
  • King Pharmaceuticals
  • Kingsbury Capital Partners
  • Kitasato Daiichi Sankyo Vaccine
  • Knight Therapeutics
  • Kolltan Pharmaceuticals
  • Kyowa Hakko Kirin
  • Kyowa Kirin
  • Laboratorios Liomont
  • Lapeyronie Hospital
  • Lenis Medical
  • LEO Pharma
  • Leukocare Biotechnology
  • Lindy Biosciences
  • Lineage Therapeutics
  • Lundbeck
  • Lupin
  • Luye Pharma
  • Manchester Institute of Biotechnology
  • Maruho
  • Maruishi Pharmaceutical
  • Massachusetts Institute of Technology
  • MaxiVAX
  • McNair Group
  • Medac Pharma
  • Medical International Technology
  • Medicalchain
  • Medicom Innovation Partner
  • MedImmune
  • MedinCell
  • Medipacs
  • MedPro
  • Medtronic
  • Medtrum
  • Merck
  • Merieux Développement
  • MGlas
  • MicroVAX
  • Mika Medical
  • MilliporeSigma
  • Miracle Medical
  • Mitsubishi Gas Chemical
  • Mitsubishi Tanabe Pharma
  • MJ Biopharm
  • Momenta Pharmaceuticals
  • Morphogenesis
  • MorphoSys
  • Mylan
  • Nano Precision Medical
  • NantCell
  • National Cancer Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of Neurological Disorders and Stroke
  • The National Medical Products Administration
  • Nektar Therapeutics
  • Nemera
  • Neumedicines
  • Neurimmune
  • NeuroDerm
  • NGM Biopharmaceuticals
  • Ningbo Zhengli Pharmaceutical Packing
  • Nippon Organon
  • Nipro Medical
  • Nordic Group
  • Novartis
  • Novimmune
  • Novo Nordisk
  • NPS Pharmaceuticals
  • Nuance Designs
  • Numab
  • Nuova Ompi
  • OBI Pharma
  • Omeros
  • Ompi
  • Oncolix
  • OPKO Health
  • OrbiMed
  • Orphan Technologies
  • Otsuka Pharmaceutical
  • Oval Medical Technologies
  • Owen Mumford
  • Oxford Finance
  • PA Consulting
  • Pacira BioSciences
  • Palmetto Partners
  • PaxVax
  • Pendiq
  • Penjet
  • Pfizer
  • PharmaJet
  • Pharmakon Advisors
  • PharmaSens
  • Pharmstandard
  • PhaseBio Pharmaceuticals
  • PHC Injection Device Technologies
  • Philogen
  • Phoundry Pharmaceuticals
  • Plas-Tech Engineering
  • Polfa Tarchomin
  • Population Council
  • Portal Instruments
  • Primequal
  • ProJect Pharmaceutics
  • Prolynx
  • Promius Pharma
  • ProteoThera
  • Provenance Biopharmaceuticals
  • Pulse NeedleFree Systems
  • QS Medical Technology
  • Qu Biologics
  • RA Capital Management
  • Receptos
  • Recon Therapeutics
  • Redmile Group
  • ReForm Biologics
  • Regeneron Pharmaceuticals
  • REMD Biotherapeutics
  • RemeGen
  • Rentschler Biotechnologie
  • Revolutions Medical
  • Rhône-Poulenc Rorer
  • RMS Medical Products
  • Roche
  • Rock Springs Capital
  • Roselabs Bioscience
  • ROXALL Medizin
  • R-Pharm
  • Sabby Management
  • Salix Pharmaceuticals
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Santen Pharmaceutical
  • Schering-Plough
  • Schott
  • Scripps Research Institute
  • Sensile Medical
  • Seqirus
  • Serina Therapeutics
  • Sernova
  • Serum Institute of India
  • Sewa Medicals
  • Shandong Pharmaceutical Glass
  • Shandong Weigao
  • Shandong Zibo Minkang Pharmaceutical Packing
  • Shanghai Dahua Pharmaceutical
  • Shanghai JMT-Bio
  • Shanghai Junshi Biosciences
  • Shanghai Umitai Medical Technology
  • Shenzhen Salubris Pharmaceuticals
  • Shin Yan Sheno Precision Industrial
  • Shire
  • SHL Medical
  • Shreya Life Sciences
  • Silicon Valley Bank
  • Sinocelltech
  • SiO2 Medical Products
  • SK Chemicals
  • Société Générale Asset Management
  • Sofinnova Partners
  • Solteam Medical
  • SOOIL Development
  • SOTIO
  • Spectrum Pharmaceuticals
  • Square Pharmaceuticals
  • STADA Arzneimittel
  • SteadyMed Therapeutics
  • Stemirna Therapeutics
  • Subcuject
  • Sumitomo Dainippon Pharma
  • Sun Pharmaceutical Industries
  • Swedish Orphan Biovitrum
  • Synermore Biologics
  • Synthon Hispania
  • Taisei Kako
  • Taisho Pharmaceutical
  • Takeda Pharmaceutical
  • Talecris Biotherapeutics
  • Tandem Diabetes Care
  • Technical University of Munich
  • Telegraph Hill Partners
  • TerSera Therapeutics
  • Terumo
  • Teva Pharmaceuticals
  • Texan Allergy & Sinus Center
  • Texas Diabetes Institute
  • Texas Emerging Technologies Fund
  • The National Institute for Health and Care Excellence
  • The National Medical Products
  • The Wyss Institute at Harvard University
  • TheraCyte
  • Theralpha
  • Tianjin SinoBiotech
  • Titan Pharmaceuticals
  • Tonghua Dongbao
  • Torii Pharmaceutical
  • Touche Medical
  • Transcoject
  • Transgene
  • TREOS Bio
  • Tyfill Pharmapack
  • U.S. Medical Instruments
  • UCB Pharma
  • Ultragenyx Pharmaceutical
  • Uman Pharma
  • Uni-Bio Science Group
  • Unilever
  • Unilife
  • Union Medico
  • United BioPharma
  • United Therapeutics
  • University of Colorado
  • University of Texas Health Science Center
  • US WorldMeds
  • Valeant Pharmaceuticals
  • Valeritas
  • Venrock
  • Ventana Medical Systems
  • Vetter Pharma
  • ViaCyte
  • ViCentra
  • Viela Bio
  • ViiV Healthcare
  • ViroMed
  • ViroPharma
  • Vitaeris
  • Vivo Capital
  • Wanhai Medical
  • West Pharmaceutical Services
  • Wild Basin Investments
  • XBiotech
  • Xellia Pharmaceuticals
  • XEME Biopharma
  • Xencor
  • Xeris Pharmaceuticals
  • YangZhong Wealth Metal
  • Youlyy Industrial
  • Ypsomed
  • Zensun
  • Zogenix
  • Zweite TechnoStart Ventures Fonds
Note: Product cover images may vary from those shown
4 of 4

 

 

Loading
LOADING...

Adroll
adroll